



Press release
March 15, 2019
Gothenburg

EmbryoScope+ approved for sales in China

Vitrolife AB (publ) has today received market approval for the time-lapse incubator EmbryoScope+ in China, the world's largest market measured in terms of number of IVF treatments.

EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. In 2018, Vitrolife received market approval in China for the EmbryoScope time-lapse system, with capacity for six patients. "We are delighted to receive market approval in China for EmbryoScope+, whose high capacity fits well with the large Chinese clinics," says Thomas Axelsson, CEO of Vitrolife.

March 15, 2019
Gothenburg
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Contact persons:

Thomas Axelsson, CEO, tel: +46 31 721 80 01
Mikael Engblom, CFO, tel: +46 31 721 80 14

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction.

Vitrolife today has approximately 390 employees and the company's products are sold in approximately 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 8.30 am CET on March 15, 2019.